Dong G - Search Results

1

Design of paediatric trials with benefit-risk endpoints using a composite score of adverse events of interest (AEI) and win-statistics.

Seifu Y, Mt-Isa S, Duke K, Gamalo-Siebers M, Wang W, Dong G, Kolassa J. Seifu Y, et al. Among authors: dong g. J Biopharm Stat. 2023 Nov 2;33(6):696-707. doi: 10.1080/10543406.2022.2153202. Epub 2022 Dec 22. J Biopharm Stat. 2023. PMID: 36545791

2

The stratified win ratio.

Dong G, Qiu J, Wang D, Vandemeulebroecke M. Dong G, et al. J Biopharm Stat. 2018;28(4):778-796. doi: 10.1080/10543406.2017.1397007. Epub 2017 Nov 27. J Biopharm Stat. 2018. PMID: 29172988

3

The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.

Dong G, Huang B, Chang YW, Seifu Y, Song J, Hoaglin DC. Dong G, et al. Pharm Stat. 2020 May;19(3):168-177. doi: 10.1002/pst.1977. Epub 2019 Oct 31. Pharm Stat. 2020. PMID: 31671481

4

The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.

Dong G, Mao L, Huang B, Gamalo-Siebers M, Wang J, Yu G, Hoaglin DC. Dong G, et al. J Biopharm Stat. 2020 Sep 2;30(5):882-899. doi: 10.1080/10543406.2020.1757692. Epub 2020 Jun 17. J Biopharm Stat. 2020. PMID: 32552451 Free PMC article.

5

Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.

Dong G, Huang B, Verbeeck J, Cui Y, Song J, Gamalo-Siebers M, Wang D, Hoaglin DC, Seifu Y, Mütze T, Kolassa J. Dong G, et al. Pharm Stat. 2023 Jan;22(1):20-33. doi: 10.1002/pst.2251. Epub 2022 Jun 27. Pharm Stat. 2023. PMID: 35757986

6

The win odds: statistical inference and regression.

Song J, Verbeeck J, Huang B, Hoaglin DC, Gamalo-Siebers M, Seifu Y, Wang D, Cooner F, Dong G. Song J, et al. Among authors: dong g. J Biopharm Stat. 2023 Mar;33(2):140-150. doi: 10.1080/10543406.2022.2089156. Epub 2022 Aug 10. J Biopharm Stat. 2023. PMID: 35946932 Review.

7

Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials.

Cui Y, Dong G, Kuan PF, Huang B. Cui Y, et al. Among authors: dong g. J Biopharm Stat. 2023 May 4;33(3):272-288. doi: 10.1080/10543406.2022.2141769. Epub 2022 Nov 7. J Biopharm Stat. 2023. PMID: 36343174

8

The stratified win statistics (win ratio, win odds, and net benefit).

Dong G, Hoaglin DC, Huang B, Cui Y, Wang D, Cheng Y, Gamalo-Siebers M. Dong G, et al. Pharm Stat. 2023 Jul-Aug;22(4):748-756. doi: 10.1002/pst.2293. Epub 2023 Feb 20. Pharm Stat. 2023. PMID: 36808217

9

Adjusting win statistics for dependent censoring.

Dong G, Huang B, Wang D, Verbeeck J, Wang J, Hoaglin DC. Dong G, et al. Pharm Stat. 2021 May;20(3):440-450. doi: 10.1002/pst.2086. Epub 2020 Nov 28. Pharm Stat. 2021. PMID: 33247544

10

A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.

Dong G, Li D, Ballerstedt S, Vandemeulebroecke M. Dong G, et al. Pharm Stat. 2016 Sep;15(5):430-7. doi: 10.1002/pst.1763. Epub 2016 Aug 2. Pharm Stat. 2016. PMID: 27485522

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,366 results

Search Page